TUXUMDON SARATONI IMMUN LANDSHAFTINI TUSHUNISH: IGCH CD4+, CD8+ VA PD-L1 NING O‘SMA MIKROMUHITIDAGI O‘RNI VA ULARNING DAVOLASHGA TA’SIRI
Abstrakt
Dolzarbligi. Tuxumdon saratoni dunyodagi eng oʻlim darajasi yuqori boʻlgan ginekologik xavfli oʻsmalardan biri boʻlib, asosan kech tashxis qoʻyilishi va samarali erta skrining usullarining yoʻqligi tufayli yuqori oʻlim ko'rsatkichiga ega. O‘sma mikromuhiti (O’MM) saraton rivojlanishi, immun tizimdan qochish va terapiyaga chidamliligida muhim rol o‘ynaydi. Immun hujayralar, xususan CD4+ va CD8+ T hujayralari, shuningdek, PD-L1 kabi immun nazorat nuqtalari o‘smaning xatti-harakatlari va terapiyaga javobini sezilarli darajada ta’sir qiladi. Ularning tuxumdon saratonda tutgan o‘rni yangi immunoterapevtik strategiyalarni ishlab chiqishda muhim ahamiyatga ega. Materiallar va tadqiqot usullari. Ushbu tadqiqotga Samarqand filiali Respublikasi Ixtisoslashtirilgan Onkologiya va Radiologiya Ilmiy-Amaliy Tibbiyot Markazining 135 nafar tuxumdon saratoni bilan kasallangan bemorlari kiritildi. O‘sma namunalar biopsiya yoki jarrohlik yo‘li bilan olingan, immun profillash multiplex immunogistoximiya va oqim sitometriyasi yordamida amalga oshirildi. CD4+, CD8+ va PD-L1 darajalari miqdoriy jihatdan baholandi va ularning o’sma mikromuhiti ichidagi taqsimoti tahlil qilindi. Immun profillar va klinik natijalar, shu jumladan, yashash darajasi va immunoterapiyaga javob o‘rtasidagi bog‘liqliklar o‘rganildi. Tadqiqot natijalari. CD4+ T helper hujayralari funktsional xilma-xillikka ega bo‘lib, Th1 hujayralari IFN-γ orqali o‘sma qarshi immunitetni rag‘batlantirdi, Th2 va regulyator T hujayralari (Treg) esa rivojlangan bosqichdagi o‘sma immunosupressiyasiga sabab bo‘ldi. CD8+ T hujayralarining yuqori infiltratsiyasi yaxshiroq yashash darajasi bilan bog‘liq edi, ammo PD-L1 darajasining oshishi ularning charchashiga (PD-1, TIM-3, LAG-3) va immun tizimidan qochishiga sabab bo‘ldi. PD-L1 ning yuqori darajada ifodalanishi yomon prognoz bilan bog‘liq bo‘lib, uning immun nazorat nuqtasi sifatidagi muhim rolini tasdiqlaydi. Xulosa. Ushbu tadqiqot CD4+, CD8+ va PD-L1 ekspressiyasining tuxumdon saratonda prognostik ahamiyatini ta’kidlaydi. Immun profillash target terapiya strategiyalarini ishlab chiqishda yordam berishi mumkin, bu esa immunoterapiyaning samaradorligini optimallashtiradi. Kelajakdagi tadqiqotlar bemorlarni tabaqalashtirish va terapevtik natijalarni yaxshilash uchun multi-omika yondashuvlarini integratsiyalashga qaratilishi kerak.
Mualliflar haqida
Adabiyotlar ro'yxati
Wang, Y., Zhou, Y., Yang, L., et al. (2024). Spatial heterogeneity expression of PD‐L1 in cancer therapy. Advanced Science, 11(1), 2303175.
Lotze, M. T., Olejniczak, S. H., & Skokos, D. (2024). CD28 co-stimulation: Novel insights in cancer immunotherapy. Nature Reviews Immunology.
Ren, X., Wang, L., Liu, L., et al. (2024). PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy. Frontiers in Immunology, 15, 1392546.
Mima, Y., Ohtsuka, T., Ebato, I., et al. (2024). T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment. Biomedicines, 12(8), 1886.
Ni, R., Hu, Z., & Tao, R. (2024). Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer. Biomedicine & Pharmacotherapy, 179, 117430.
Johnson, D. B., Estrada, M. V., Salgado, R., et al. (2024). Immune profiling in gynecologic cancers: a biomarker approach. Journal of Clinical Oncology, 42(3), 204-215.
Miller, A. M., Lundberg, I. V., Ozbek, U., et al. (2024). Tumor-infiltrating lymphocytes in ovarian cancer: their prognostic role and therapeutic implications. Cancer Immunology Research, 12(5), 765-780.
Nakamura, K., Smyth, M. J., & Martinet, L. (2024). Role of natural killer cells in ovarian cancer and the impact of checkpoint blockade therapy. Nature Cancer Reviews, 5(2), 142-156.
White, E. E., Rhodes, S. D., et al. (2024). The NF1+/-Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation. Cancers, 16(5), 994.
Lawton, M. L., Inge, M. M., Blum, B. C., et al. (2024). Multiomic profiling of chronically activated CD4+ T cells identifies drivers of exhaustion and metabolic reprogramming. PLoS Biology, 22(12), e3002943.
Hashemi, M., Khosroshahi, E. M., Daneii, P., et al. (2024). Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response. Non-coding RNA Research.
Wang, X., Yang, M., Zhu, J., et al. (2024). Role of exosomal non coding RNAs in ovarian cancer. International Journal of Molecular Medicine, 54(4), 87.
Elemam, N. M., Mekky, R. Y., Rashid, G., et al. (2024). Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology. Expert Reviews in Molecular Medicine, 26, e1.